Strongbridge Biopharma plc to Present at the Canaccord Genuity 37th Annual Growth Conference
DUBLIN, Ireland and TREVOSE, Pa., Aug. 10, 2017 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at the Canaccord Genuity 37th Annual Growth Conference, taking place August 9-10, 2017 at the InterContinental in Boston.
Matthew Pauls, president and chief executive officer of Strongbridge Biopharma, will provide a corporate overview on Thursday, August 10 at 3:00 p.m. ET. The presentation will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.
About Strongbridge Biopharma
Strongbridge Biopharma is a commercial-stage global biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge’s lead compounds include RECORLEV™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing’s syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in Cushing’s syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide have received orphan designation from the U.S. Food and Drug Administrationand the European Medicines Agency. For more information, visit www.strongbridgebio.com.
Contacts: Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 lrocco@elixirhealthpr.com Investor Relations U.S.: The Trout Group Marcy Nanus +1 646-378-2927 mnanus@troutgroup.comEurope: First House Mitra Hagen Negård +47 21 04 62 19 strongbridgebio@firsthouse.noUSA900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
Source: Strongbridge
